Participating Centers & Contacts

Business indexAlgisyl®, LoneStar Heart's device for the treatment of heart failure patients with a dilated left ventricle, has not been globally approved for sale and can only be accessed by physicians and patients through company-sponsored clinical studies with the exception of Europe where Algisyl® received CE mark approval in October 2014 and can be sold in the European Union.

LoneStar Heart frequently commences and completes clinical trials, so please check back here often for news on new and existing trials worldwide. Should you have questions about potential treatment with Algisyl in the European Union please write an email to either This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it.